Verastem filed a new-drug application seeking full approval from the FDA for duvelisib for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, plus accelerated approval for relapsed/refractory follicular lymphoma. Verastem's filing includes data from its DUO trial, which showed duvelisib diminished the risk of disease progression or death by 48% compared with Arzerra, or ofatumumab, in patients with relapsed/refractory CLL/SLL, and the DYNAMO study, in which the drug showed an overall response rate of 41% in patients with follicular lymphoma.
About 350,000 of the 1.2 million Americans infected with HIV do not receive treatment, and adherence is a problem for many of those who do receive treatment, says Express Scripts consultant Aimee Tharaldson. Several new drugs expected to receive FDA approval this year -- three oral and one intravenous -- might improve adherence.
McKesson Medical-Surgical has signed a deal to distribute Sysmex's XW-100 automated hematology analyzer.
Tennessee Army National Guard Sgt. Matthan Fish, who died after a motorcycle crash, was a registered donor, and 50 people will benefit from his tissues while a veteran will receive a kidney. "He was an all-American hero, and I mean that," said his father, Robert Fish.
LifeLink Legacy Fund will host its third yearly Love Give Live 5K Walk/Run on Saturday to raise funds for LifeLink and Donate Life Florida. The groups support donor education.
Anika Therapeutics partnered with the Institute of Integrative Biology at the University of Liverpool on a three-year collaboration to develop a treatment for osteoarthritis using injectable mesenchymal stem cells.
A study in the journal Science Advances says researchers with the Morgridge Institute found that viruses produce pores in cellular walls to allow replication, creating a potential target for treatment of diseases such as hepatitis C. "The fact that a common replication pathway for positive sense RNA viruses that uses host membrane pores was discovered could lead to the development of antivirals targeting this large group of viruses," said Dr. Amesh Adalja of the Johns Hopkins University Center for Health Security.
A study by a team of researchers from the US, the Netherlands and Mali found that malaria patients responded to a combination of artemisinin-based therapy and methylene blue dye. Patients did not transmit the malaria parasite within two days after treatment, compared with a week or more using standard treatment, according to the study in the journal The Lancet Infectious Diseases.
Two studies, one in the journal Nature Medicine and the other in the journal Nature Communications, provided additional input on the effect of the Zika virus on infants. The first explored how Zika can affect the brains of infants with normal-sized heads, and the second found hints that genetics may be a factor in how susceptible some infants are to Zika-related birth defects.